Su Xiaodan, Su Mingzhe, Guo Erchu, Zhou Yan, Yang Xingye, Li Suxin, Ye Yong
School of Pharmacy, Guangxi Medical University, Nanning 530021, China.
Department of Molecular Vascular Physiology, Kanazawa University Graduate School of Medical Science, Takaramachi, Kanazawa University, Ishikawa 920-8640, Japan.
ACS Nano. 2025 Jul 29;19(29):26296-26319. doi: 10.1021/acsnano.5c04463. Epub 2025 Jul 18.
Nanoparticles (NPs) coated with macrophage membranes have recently emerged as promising tools in nanomedicine due to their properties, including immune evasion, extended blood circulation, cell-specific targeting, and precise molecular recognition. Recently, the view of classification of macrophages into M1 and M2 types has been considered overly simplistic, as it overlooks the complexity of different kinds of tumor microenvironment. However, most current systems utilize M1-type macrophages as membrane sources, raising concerns about their tumor promoting potential, and tumor barriers restrict direct drug diffusion. In contrast, tissue-resident macrophages represent a promising approach for developing tumor targeting nanodevices. Their tissue-specific homing ability allows them to bypass immune surveillance and migrate to sites of inflammation. Furthermore, they possess a significant capacity to regulate T cell immune function, influencing tumor progression and maintaining tissue homeostasis. These targeting and immunomodulatory capabilities are attributed to the surface expression of tissue-specific biomolecules. Membrane-coated nano delivery systems derived from tissue macrophages offer enhanced therapeutic efficacy and safety by promoting prolonged circulation and improving drug accumulation at target sites. This review highlights the advantages and future potential of using tissue-resident macrophage membranes as multifunctional biomimetic surface functionalization for nanoparticle camouflaging in tumor therapy. It also examines the origins of tissue macrophages, their roles in T cell immune regulation, and strategies for engineering macrophage membrane-coated nanoparticles, with a focus on fabrication types and therapeutic prospects.
近年来,包覆巨噬细胞膜的纳米颗粒(NPs)作为纳米医学领域颇具前景的工具崭露头角,这得益于其具备的免疫逃逸、延长血液循环时间、细胞特异性靶向以及精确分子识别等特性。近来,将巨噬细胞分为M1型和M2型的分类观点被认为过于简单,因为它忽略了不同种类肿瘤微环境的复杂性。然而,当前大多数系统都利用M1型巨噬细胞作为膜源,这引发了对其促肿瘤潜力的担忧,而且肿瘤屏障会限制药物的直接扩散。相比之下,组织驻留巨噬细胞是开发肿瘤靶向纳米装置的一种很有前景的方法。它们的组织特异性归巢能力使它们能够绕过免疫监视并迁移到炎症部位。此外,它们具有显著的调节T细胞免疫功能的能力,影响肿瘤进展并维持组织稳态。这些靶向和免疫调节能力归因于组织特异性生物分子的表面表达。源自组织巨噬细胞的膜包覆纳米递送系统通过促进血液循环延长和改善药物在靶位点的积累,提高了治疗效果和安全性。本综述重点介绍了使用组织驻留巨噬细胞膜作为多功能仿生表面功能化材料用于肿瘤治疗中纳米颗粒伪装的优势和未来潜力。它还研究了组织巨噬细胞的来源、它们在T细胞免疫调节中的作用以及工程化巨噬细胞膜包覆纳米颗粒的策略,重点关注制备类型和治疗前景。